Sponsor bio page for CanCan Diagnostics

Bio

Based in Edinburgh and spun out from the University of Edinburgh in September 2022, CanCan Diagnostics is focusing on transforming veterinary oncology with advanced diagnostic tools. As the visionary behind CanCan Diagnostics, Maciej’s background in veterinary science and oncology is the cornerstone of our product innovation. His doctoral research in the US and subsequent achievements in the field, including prestigious awards and contributions to leading oncology textbooks, have positioned him as a leading figure in canine cancer molecular biology. CanCan’s mission is to revolutionise cancer diagnostics in pets using next-generation liquid biopsy technology, significantly improving early cancer detection and monitoring through non-invasive methods. CanCan Diagnostics recently launched flagship product, K9-LiquiDx™, launched in Q1 2024, is a next-generation sequencing-based liquid biopsy panel designed to aid diagnosis and monitor canine cancer through a minimally invasive blood test that analyses circulating tumour DNA (ctDNA). The non-invasive nature of CanCan’s diagnostics, coupled with high accuracy and early relapse detection capabilities, positions it uniquely against traditional invasive methods. We look forward to sharing with you this exciting technology and the benefits it can bring to the world of veterinary and pet health.